Literature DB >> 9889973

DNA vaccines. Mechanisms for generation of immune responses.

M A Liu1, T M Fu, J J Donnelly, M J Caulfield, J B Ulmer.   

Abstract

Mesh：

Substances：

Year:  1998        PMID： 9889973

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN： 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  10 in total

1.  Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins.

Authors:  T M Ross; Y Xu; T D Green; D C Montefiori; H L Robinson
Journal:  AIDS Res Hum Retroviruses       Date:  2001-06-10       Impact factor: 2.205

Review 2.  Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.

Authors:  Ajay P Singh; Shantibhusan Senapati; Moorthy P Ponnusamy; Maneesh Jain; Subodh M Lele; John S Davis; Steven Remmenga; Surinder K Batra
Journal:  Lancet Oncol       Date:  2008-11       Impact factor: 41.316

3.  Cancer therapy using a self-replicating RNA vaccine.

Authors:  H Ying; T Z Zaks; R F Wang; K R Irvine; U S Kammula; F M Marincola; W W Leitner; N P Restifo
Journal:  Nat Med       Date:  1999-07       Impact factor: 53.440

4.  Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.

Authors:  M A Egan; W A Charini; M J Kuroda; J E Schmitz; P Racz; K Tenner-Racz; K Manson; M Wyand; M A Lifton; C E Nickerson; T Fu; J W Shiver; N L Letvin
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Enhanced immunogenicity to food-and-mouth disease virus in mice vaccination with alphaviral replicon-based DNA vaccine expressing the capsid precursor polypeptide (P1).

Authors:  Xiaolan Yu; Shaobo Xiao; Liurong Fang; Yunbo Jiang; Huanchun Chen
Journal:  Virus Genes       Date:  2006-12       Impact factor: 2.332

Review 6.  Technologies to improve immunisation safety.

Authors:  C J Clements; M T Aguado; L Jódar
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

7.  Unique V3 loop sequence derived from the R2 strain of HIV-type 1 elicits broad neutralizing antibodies.

Authors:  Kelly R Young; Benjamin E Teal; Yvonne Brooks; Thomas D Green; Joseph F Bower; Ted M Ross
Journal:  AIDS Res Hum Retroviruses       Date:  2004-11       Impact factor: 2.205

8.  C3d enhances immune responses using low doses of DNA expressing the HIV-1 envelope from codon-optimized gene sequences.

Authors:  Joseph F Bower; Kelly L Sanders; Ted M Ross
Journal:  Curr HIV Res       Date:  2005-04       Impact factor: 1.581

9.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.

Authors:  Thomas D Green; David C Montefiori; Ted M Ross
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.